Cimpress Plc CMPR 深 沪
已收盘 02-06 16:00:00 美东时间
75.64
+2.060
+2.80%
华盛通- 最 高76.35
- 今 开74.25
- 成交量 9.22万股
- 最 低 71.1201
- 昨 收 73.58
- 总市值 18.37亿
- 52周最高 82.43
- 市盈率 静 129.70
- 换手率 0.38%
- 52周最低 35.21
- 委 比 63.93%
- 总股本 2428.52万
- 历史最高 171.76
- 量 比 0.52
- 振 幅 7.11%
- 历史最低 18.00
- 每 手 1
- 风险率 11.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Cimpress Raises FY2026 Sales Guidance from $3.573B-$3.607B to $3.641B-$3.675B
Cimpress (NASDAQ:CMPR) raises FY2026 sales outlook from $3.573 billion-$3.607 billion to $3.641 billion-$3.675 billion.
01-29 05:22
Cimpress Q2 EPS $1.95 Beats $1.64 Estimate, Sales $1.402B Beat $993.750M Estimate
Cimpress (NASDAQ:CMPR) reported quarterly earnings of $1.95 per share which beat the analyst consensus estimate of $1.64 by 18.9 percent. This is a 17.37 percent decrease over earnings of $2.36 per share from the same
01-29 05:08
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
A Look Ahead: Cimpress's Earnings Forecast
Cimpress (NASDAQ:CMPR) is preparing to release its quarterly earnings on Wednes...
01-28 04:02
Barrington Research Maintains Outperform on Cimpress, Maintains $83 Price Target
Barrington Research analyst Kevin Steinke maintains Cimpress (NASDAQ:CMPR) with a Outperform and maintains $83 price target.
01-27 21:10
Cimpress Shareholders Approve 2025 Governance and Capital Measures
Cimpress ( ($CMPR) ) has shared an announcement. On 17 December 2025, Cimpress ...
2025-12-23 05:53
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Barrington Research Maintains Outperform on Cimpress, Raises Price Target to $83
Barrington Research analyst Kevin Steinke maintains Cimpress (NASDAQ:CMPR) with a Outperform and raises the price target from $77 to $83.
2025-11-18 03:20
Cimpress shares are trading higher after the company reported better-than-expected Q1 financial results.
Cimpress shares are trading higher after the company reported better-than-expec...
2025-10-31 03:40
